Metrics to compare | CYDY | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCYDYPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.9x | −2.7x | −0.2x | |
PEG Ratio | 0.04 | −0.04 | 0.00 | |
Price/Book | −3.5x | 2.2x | 2.6x | |
Price / LTM Sales | - | 122.7x | 2.8x | |
Upside (Analyst Target) | - | 148.9% | 60.9% | |
Fair Value Upside | Unlock | 16.4% | 9.5% | Unlock |
CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications. The company develops leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19. Its leronlimab completed phase 2 development for the treatment of micro-satellite stable colorectal cancer, and solid tumors in oncology, such as metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.